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Abstract
Background: Alkylphosphocholines constitute a novel class of antineoplastic synthetic phospholipid
derivatives that induce apoptosis of human tumor cell lines by targeting cellular membranes. We could
recently show that the first intravenously applicable alkylphosphocholine erucylphosphocholine (ErPC) is
a potent inducer of apoptosis in highly resistant human astrocytoma/glioblastoma cell lines in vitro. ErPC
was shown to cross the blood brain barrier upon repeated intravenous injections in rats and thus
constitutes a promising candidate for glioblastoma therapy. Aim of the present study was to analyze
putative beneficial effects of ErPC and its clinically more advanced derivative erucylphosphohomocholine
(erucyl-N, N, N-trimethylpropanolaminphosphate, ErPC3, Erufosine™ on radiation-induced apoptosis
and eradication of clonogenic tumor cells in human astrocytoma/glioblastoma cell lines in vitro.
Results:  While all cell lines showed high intrinsic resistance against radiation-induced apoptosis as
determined by fluorescence microscopy, treatment with ErPC and ErPC3 strongly increased sensitivity of
the cells to radiation-induced cell death (apoptosis and necrosis). T98G cells were most responsive to the
combined treatment revealing highly synergistic effects while A172 showed mostly additive to synergistic
effects, and U87MG cells sub-additive, additive or synergistic effects, depending on the respective
radiation-dose, drug-concentration and treatment time. Combined treatment enhanced therapy-induced
damage of the mitochondria and caspase-activation. Importantly, combined treatment also increased
radiation-induced eradication of clonogenic T98G cells as determined by standard colony formation
assays.
Conclusion: Our observations make the combined treatment with ionizing radiation and the membrane
targeted apoptosis modulators ErPC and ErPC3 a promising approach for the treatment of patients
suffering from malignant glioma. The use of this innovative treatment concept in an in vivo xenograft setting
is under current investigation.
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Background
During the last decades there has been only little progress
in the therapy of malignant glioma including the most
aggressive manifestation glioblastoma multiforme
(GBM). This infiltrative and destructive growing tumor is
still almost uniformly fatal with a life expectancy of a few
weeks to several months. Standard therapy consisting of
surgery with postoperative external-beam radiation ther-
apy (RT) prolongs median survival times to 9–12 months
with almost no benefit of refined surgery, aggressive
chemotherapy or improved technology of radiation ther-
apy [1-4]. In this regard, low intrinsic sensitivity of the
malignant cells to ionizing radiation and standard DNA-
damaging drugs constitutes one of the critical parameters
for treatment failure. Thus, novel treatment approaches
are badly needed to improve prognosis of GBM patients.
Since defective apoptosis can contribute to treatment
resistance aberrant apoptosis signaling pathways of tumor
cells constitute an attractive target for the modulation of
therapy response.
There is accumulated evidence that treatment with ioniz-
ing radiation or DNA-damaging drugs triggers activation
of the intrinsic, death receptor-independent death path-
way. This pathway critically involves alterations of mito-
chondrial function including breakdown of the
mitochondrial membrane potential and release of cyto-
chrome c. A cytoplasmic complex composed of cyto-
chrome c, the adapter protein Apaf-1, dATP and pro-
caspase-9, the apoptosome, enables the proteolytic activa-
tion of initiator caspase-9 that subsequently triggers the
effector caspase cascade [5]. Pro- and anti-apoptotic pro-
teins of the Bcl-2 family function as important regulators
of this mitochondrial death pathway.
The major signaling pathway triggering DNA-damage-
induced apoptosis upstream of the mitochondria involves
transcriptional activation of the tumor suppressor p53.
P53 triggers up-regulated expression of the pro-apoptotic
Bcl-2 family member Bax and Bax-induced mitochondrial
damage [6-8]. Apart from Bax, further p53-regulated pro-
apoptotic Bcl-2 proteins such as the BH-3 only proteins
Puma and Noxa can similarly participate in the regulation
of mitochondrial permeability and trigger the intrinsic,
mitochondrial death pathway for apoptosis execution [9-
11]. In addition to transcriptional activation of p53,
release of the proapoptotic lipid second messenger cera-
mide from cellular membranes via the action of acid
sphingomyelinase (ASM) has been described as an impor-
tant mediator of radiation-induced apoptosis upstream of
the mitochondria (for review see [12]) involving Bax-
mediated mitochondrial alterations [13].
During tumorigenesis tumor cells often acquire mutations
related to apoptosis resistance. Among the signaling mol-
ecules found to be altered or defective in malignant gli-
oma, members of the apoptosis signaling cascade (p53,
Bcl-2; for review see [14]) as well as survival modulators
indirectly involved in apoptosis regulation (PI3K/PKB-
pathway; for review see [15]) have been identified [16-
18]. Consequently, novel anti-neoplastic agents that tar-
get those aberrant apoptosis and/or survival pathways
may be suited to overcome intrinsic resistance of malig-
nant glioma. In particular, a combination of radiation
therapy with an apoptosis modulator that overrides radi-
ation resistance should be useful to increase the therapeu-
tic response to ionizing radiation [19].
In this regard, alkylphosphocholines (APC), a structural
class of antineoplastic synthetic phospholipid analogs,
have been identified as promising apoptosis modulators
with a high potential value for the treatment of malignant
glioma. These membrane targeted drugs exert potent cyto-
static and cytotoxic effects in vitro as well as in animal
models. They affect both apoptotic and survival signal
transduction pathways, including activation of the pro-
apoptotic SAPK/JNK pathway and inhibition of the
mitogenic MAPK/ERK and PI3K-Akt/PKB survival path-
ways (for a review see [20,21]).
Interestingly, synthetic phospholipid analogs display
almost no cross resistance towards standard DNA-damag-
ing drugs and ionizing radiation in vitro [22-26] and
unpublished data). In contrast, combined treatment with
DNA-damaging anticancer drugs and ionizing radiation
point to additive or synergistic effects [22,25,27,28].
These promising in vitro and preclinical data suggest that
these membrane targeted apoptosis modulators may be
suited for administration as single drugs as well as in com-
bination with radiation therapy to overcome resistance to
standard treatment concepts.
Since in the case of malignant glioma, the use of apoptosis
targeting agents that cross the blood-brain barrier is man-
datory, the prototypical intravenously applicable APC-
derivative ErPC is most promising for the treatment of
malignant glioma: Apart from potent cytotoxic efficacy on
human malignant astrocytoma/glioblastoma cell lines in
vitro  [20,24,29,30] pharmacokinetic experiments with
healthy rats revealed that ErPC is able to cross the blood
brain barrier. Upon repeated intravenous applications of
nontoxic drug doses an accumulation in brain tissue
could be observed. Moreover, in glioma-bearing rats an
accumulation in tumor tissue was also demonstrated
[31,32].
To provide a scientific basis for the use of ErPC and its
structural derivative ErPC3 in combination with ionizing
radiation, aim of the present study was to analyze putative
beneficial effects of ErPC and ErPC3 on radiation inducedRadiation Oncology 2006, 1:6 http://www.ro-journal.com/content/1/1/6
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apoptosis and eradication of clonogenic tumor cells in
human astrocytoma/glioblastoma cell lines in vitro.
Results
ErPC induces time- and concentration-dependent 
apoptosis in human malignant glioma cell lines
We have shown earlier that induction of apoptosis via the
intrinsic pathway contributes to the antineoplastic activity
of ErPC [24,29,33]. The present study was designed to
substantiate our findings on the importance of apoptosis
for cytotoxic efficacy of ErPC in human malignant glioma.
To this end, time course and dose response relationships
for ErPC-induced cell death were analyzed in three astro-
cytoma/glioblastoma (AC/GBM) cell lines (A172, T98G
and U87MG) by fluorescence microscopy. Combined
staining with Hoechst33342 and PI allowed to differenti-
ate between apoptosis and necrosis.
Consistent with our earlier findings concentrations of 25
to 50 µM ErPC were sufficient to induce growth arrest and
apoptosis in A172 and T98G cells within 48 h of treat-
ment. This is visualized in Fig. 1A by decreased cell density
and increased numbers of cells with condensed chroma-
tin and nuclear fragmentation indicative for apoptosis
upon treatment with increasing ErPC-concentrations. In
contrast, 75 to 100 µM ErPC were required to induce sim-
ilar effects in U87MG cells (Fig 1A). Concordantly, 50 µM
ErPC strongly decreased the number of viable A172 and
T98G cells with most pronounced effects at extended
incubation times (72 h) (Fig. 1B). In contrast, U87MG
cells remained mainly unaffected by treatment with 50
µM ErPC even after 72 h of treatment (Fig. 1B). In general,
all AC/GBM cell lines tested were sensitive to the cytotoxic
effects of ErPC. ErPC triggered time- and concentration-
dependent cell death in all cell lines with T98G and A172
cells being more sensitive than U87MG cells at all time
points (Fig 1C–E).
Human malignant glioma cell lines are resistant to 
radiation-induced apoptosis
Intrinsic resistance of malignant glioma cells to ionizing
radiation contributes to treatment failure. To establish
time course and dose response relationships for radiation-
induced cell death in human malignant glioma cell lines
used in the present study, apoptotic and necrotic cell
death was quantified 24, 48 and 72 h after single dose
application of 2.5, 5 or 10 Gy. In contrast to treatment
with ErPC, T98G, A172 and U87MG cells turned out to be
rather resistant against radiation-induced apoptosis and
necrosis (Fig. 2). Even 72 h after a single dose of 10 Gy,
irradiation almost completely failed to trigger cell death in
T98G cells, A172 cells and U87MG cells resulting in cell
death rates below 20%.
ErPC sensitizes human malignant glioma cell lines to 
radiation-induced apoptosis
It has been shown that ionizing radiation as well as the
membrane targeted apoptosis modulator ErPC induce
apoptosis via the intrinsic, mitochondrial death pathway.
Despite these similarities in apoptosis execution, ErPC
was able to induce apoptosis and necrosis in malignant
glioma cell lines resistant to radiation-induced cell death
(Fig. 1). This observation constituted the rationale to eval-
uate whether combined treatment with ErPC could
increase radiation-induced cell death in human malig-
nant glioma cell lines. To this end, T98G, A172 and
U87MG cells were treated with 2.5, 5 and 10 Gy and/or 0,
12.5, 25, 50, 75 or 100 µM ErPC. ErPC was added to the
culture medium 10 min after irradiation and induction of
apoptosis and necrosis was determined 24 h, 48 h and 72
h after treatment.
As shown in Fig. 3A combined treatment of T98G cells for
48 h with 10 Gy and 50 µM ErPC clearly increased the lev-
els of radiation-induced apoptosis. Quantitative analysis
indicated that enhanced cell death induction 48 h after
combined treatment compared to either treatment alone
occurred in a dose- and concentration-dependent manner
yielding maximum levels of apoptosis in the presence of
50 µM ErPC (Fig. 3B). Moreover, at all radiation doses
tested efficacy of combined treatment depended on the
ErPC-concentration and treatment time with most pro-
nounced effects at 72 h (Fig. 3C+D and data not shown).
Similar to the results obtained with T98G-cells, combined
treatment with increasing concentrations of ErPC sensi-
tized A172 cells to radiation-induced apoptosis (Fig. 4).
As shown in Fig. 4A, irradiation with 10 Gy alone only
induced growth arrest of A172 cells (decrease in cell den-
sity) without any morphological signs for induction of
apoptosis. In contrast, treatment with 50 µM ErPC alone
induced growth arrest and apoptosis of A172 cells. How-
ever, the level of apoptotic cells further increased by com-
bined administration of both treatments (Fig. 4A).
Increased cytotoxicity of the combination was dependent
on drug-concentration and radiation dose (Fig 4B). While
the combination of 12.5 and 25 µM ErPC only slightly
increased the cytotoxic efficacy of ionizing radiation, the
combination of 50 µM with ionizing radiation efficiently
induced cell death yielding up to 57% cell kill at 50 µM
ErPC combined with 10 Gy (Fig. 4B). Again, at all radia-
tion doses tested the combined effect was clearly time-
and concentration dependent with maximal cytotoxicity
at 50 µM and 72 h of treatment (Fig. 4C+D and data not
shown).
As mentioned above, 75 to 100 µM ErPC were required to
induce significant growth arrest and apoptosis in U87MG
cells (Fig. 1A, B, E). Therefore, to test putative sensitizingRadiation Oncology 2006, 1:6 http://www.ro-journal.com/content/1/1/6
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effects of ErPC on radiation-induced cell death in U87MG
cells irradiation was combined with 0, 50, 75 and 100 µM
ErPC. Photomicrographs of the cells treated for 48 h with
10 Gy, 75 µM ErPC or the combination reveal that irradi-
ation alone yields small amounts of growth arrest and
apoptosis while treatment with 75 µM ErPC induced
strong growth arrest and increased amounts of apoptosis
compared to radiation alone (Fig. 5A). However, com-
bined treatment with 10 Gy and 75 µM ErPC resulted in a
further rise in cell death-induction (Fig. 5A).
As shown in Fig. 5B, enhanced efficacy of the combina-
tion depended on the radiation dose and the ErPC-con-
centration (Fig. 5B). Similar to the results obtained with
T98G and A172 cells, at all radiation doses tested the
response of the combined treatment increased in a time-
and concentration-dependent manner. However, in con-
ErPC induces growth arrest and apoptosis in human malignant glioma cell lines Figure 1
ErPC induces growth arrest and apoptosis in human malignant glioma cell lines. T98G, A172 and U87MG were 
treated with 0, 12.5, 25, 50, 75 or 100 µM ErPC for 24 h, 48 h and 72 h as indicated. Subsequently, induction of apoptosis and 
necrosis was analyzed by fluorescence microscopy upon combined staining with Hoechst33342 and propidium iodide (PI). 
Apoptotic and necrotic cell death was quantified by counting cells with apoptotic and necrotic morphology. The percentage of 
viable cells was calculated from the difference of total cell count (= 100%) and apoptotic (% apoptosis) plus necrotic cells (% 
necrosis) (% viable cells = 100% – (% apoptosis + % necrosis). While 25 to 50 µM ErPC were sufficient to induce growth arrest 
and apoptosis in T98G and A172 cells, 75 to 100 µM ErPC were required to induce similar effects in U87MG cells. Data show 
one representative of three independent experiments (A) or means ± s.d., n = 3 (B, C, D, E). (A) Morphologic appearance 
of human malignant glioma cell lines 48 h after treatment with the indicated ErPC-concentrations. (B) Time-dependent 
decrease in the amount of viable cells upon treatment with 50 µM ErPC. (C, D, E) Concentration-dependent decrease in the 
amount of viable (C) T98G (D) A172 and (E) U87MG cells upon ErPC-treatment.
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trast to A172 and T98G cells, maximum induction of cell
death was already observed 48 h after treatment (Fig.
5C+D and data not shown). Consistent with the compa-
rably low sensitivity of U87MG cells to ErPC, massive
rates of more than 80% cell kill required the presence of
100 µM ErPC (Fig. 5B–D).
ErPC mediates additive to synergistic sensitization effects 
on radiation-induced apoptosis
To determine how far the interactions between irradiation
and ErPC-treatment in human malignant glioma cell lines
were sub-additive, additive or even synergistic, biomathe-
matical evaluation was performed by isobologram analy-
sis. In general, sensitivity of malignant glioma cells
depended on drug concentration, radiation dose and
treatment time (Fig. 6+7). T98G were most responsive to
combined treatment showing almost exclusively synergis-
tic effects after 24 h, 48 h and 72 h of treatment. Com-
bined treatment of A172 cells revealed sub-additive to
synergistic effects after 24 h and 72 h, and synergistic
effects after 48 h of treatment. U87MG were slightly less
responsive compared to T98G and A172 with less than
additive to synergistic effects at 24 h and sub-additive to
additive effects at 48 and 72 h after treatment (Fig. 7A–C).
Representative analysis from selective combinations 48 h
after treatment are represented in Fig. 6. In T98G and
A172 cells a synergistic increase in cytotoxicity of the com-
bination was observed after 48 h of treatment with 25 µM
ErPC and 10 Gy (Fig. 6A+B), while in U87MG cells addi-
tive effects of 75 µM ErPC in combination with 10 Gy
were found (Fig. 6C).
ErPC3 sensitizes T98G cells to radiation-induced apoptosis
Based on the high responsiveness of T98G cells to ErPC
alone and in combination with radiation therapy, we
extended our studies on the ErPC-derivative ErPC3 (Eru-
fosine™) which is more advanced in clinical development
(Lars H. Lindner, unpublished data).
In a first set of experiments cytotoxic efficacy of ErPC3 was
evaluated in the most responsive T98G cells 48 h after
treatment with the same drug concentrations as used for
the ErPC-experiments (0, 12.5, 25 or 50 µM ErPC3). Sim-
ilar to ErPC, its derivative ErPC3 turned out to be a potent
inducer of growth arrest and apoptosis in T98G cells (Fig.
8A). In this regard, ErPC3 was already effective at concen-
trations of 12.5 µM and a more pronounced cytostatic and
cytotoxic activity was observed at increased drug concen-
trations (Fig. 8A+C). Given the potent apoptosis inducing
effects of ErPC3 we subsequently analyzed its putative
sensitizing effects on radiation-induced cell death. As
shown in Fig 8B combined treatment with ErPC3 and 10
Gy efficiently enhanced growth arrest and apoptotic cell
death in T98G cells compared to either treatment alone as
indicated by reduced cell density and enhanced numbers
of cells with condensed chromatin and nuclear fragmen-
tation, respectively. Increased efficacy of the combined
treatment depended on the drug-concentration and the
radiation-dose (Fig. 8C). Interestingly, maximal cytotoxic-
ity of the combination with 81% cell death was already
obtained with 25 µM ErPC3 in combination with 10 Gy
(Fig. 8C). Evaluation of the interaction between ErPC3
and ionizing radiation by isobologram analysis revealed
mostly synergistic effects as shown in Fig. 7D and 8D.
Increased efficacy of the combined treatment is at least 
partially due to enhanced apoptosis levels
In order to gain insight into the importance of apoptosis
for synergistic cell death induction by combined treat-
ment with ionizing radiation and ErPC or ErPC3 we first
analyzed the prevailing mechanism of cell death upon
combined treatment. As demonstrated in Fig. 9A+B, com-
bined treatment with 10 Gy and various concentrations of
ErPC or ErPC3 predominantely induced apoptosis com-
pared to necrosis, with the exception of 50 µM ErPC in
combination with 10 Gy. Interestingly, at equimolar drug
concentrations ErPC3 sensitized T98G cells more effi-
ciently to radiation-induced apoptosis than ErPC (Fig.
9A+B).
Specialized cellular proteases, the caspases have been
identified as major executioners of apoptotic cell death.
To further demonstrate the importance of apoptosis
induction for the sensitizing effects on radiation-induced
cell death we analyzed cleavage of the effector caspase-
substrate PARP, a nuclear protein involved in DNA repair.
While in control cells no PARP-cleavage could be
Human malignant glioma cell lines are resistant to radiation- induced cell death Figure 2
Human malignant glioma cell lines are resistant to 
radiation-induced cell death. T98G, A172 and U87MG 
were irradiated with 10 Gy. 24 h, 48 h and 72 h after treat-
ment, induction of apoptosis and necrosis was quantified by 
fluorescence microscopy counting the cells with apoptotic 
and necrotic appearance upon combined staining with 
Hoechst33342 and PI. The percentage of viable cells was cal-
culated as indicated in Fig.1. Data represent means ± s.d., n = 
3.
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detected, administration of 25 µM ErPC led to appearance
of the cleaved PARP fragment (89 kDa), indicative for cas-
pase-3 activation. In contrast, radiation up to 10 Gy was
not sufficient to induce significant PARP-cleavage (Fig. 9C
and data not shown). Enhanced cytotoxicity of combined
treatment with 25 µM ErPC and 5 Gy was accompanied by
a more prominent cleavage of PARP compared to ErPC-
treatment alone, indicative for increased caspase-activa-
tion and apoptosis (Fig. 9C).
Our earlier investigations revealed that apoptosis induc-
tion by ionizing radiation and ErPC involves alterations
of mitochondrial function including breakdown of the
mitochondrial membrane potential and release of cyto-
chrome c. To quantify apoptosis induction by an addi-
tional standard method we analyzed therapy-induced
breakdown of the mitochondrial membrane potential
(Fig. 10). In agreement with the results obtained by quan-
tification of cells with apoptotic nuclear morphology
combined treatment with ErPC increased radiation-
induced mitochondrial damage. These findings point to
increased efficacy of the combination at the level of the
mitochondria (Fig. 10A+B).
ErPC and radiation cooperate to induce cell death in T98G cells Figure 3
ErPC and radiation cooperate to induce cell death in T98G cells. T98G were irradiated with a single dose of 0, 2.5, 5 
or 10 Gy and subsequently treated with 0, 12.5, 25 or 50 µM ErPC as indicated. Induction of apoptosis and necrosis was quan-
tified 24 h, 48 h and 72 h after treatment by fluorescence microscopy counting the cells with apoptotic and necrotic morphol-
ogy upon combined staining with Hoechst 33342 and PI. The percentage of viable cells was calculated as indicated in Fig.1. Data 
show (A) one representative of three independent experiments or (B, C, D) means ± s.d. ; n = 3. (A) Photomicrographs of 
morphologic appearance of T98G cells upon treatment with medium (control), 10 Gy, 50 µM ErPC or 10 Gy and 50 µM ErPC. 
(B) Dose dependent increase in efficacy of the combination 48 h after treatment. (C and D) Time dependent increase in effi-
cacy of the combination.
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ErPC and ErPC3 reduce colony formation ability of T98G 
cells and increase radiation-induced eradication of 
clonogenic T98G cells
Up to now our data indicated that ErPC and ErPC3
increase sensitivity of AC/GBM cell lines to radiation
induced cell death, in particular apoptosis. To gain more
insight into cytotoxic efficacy of ErPC/ErPC3 treatment
alone and in combination with radiation, standard col-
ony formation assays were performed as a clinical relevant
endpoint. As shown in Figure 11A+C ErPC and ErPC3
reduced clonogenic survival of T98G at concentrations of
more than 12.5 µM. A prominent reduction of the surviv-
ing fraction was obtained upon treatment with 25 µM
ErPC. ErPC3 even more efficiently reduced clonogenic cell
survival of T98G cells: While 16 µM ErPC3 were sufficient
to eradicate 90% of clonogenic tumor cells, 20 µM ErPC
were required to induce the same effect (Fig. 11A+C).
In a next set of experiments we then tested whether com-
bined treatment with ErPC or ErPC3 would alter eradica-
tion of clonogenic tumor cells in response to ionizing
radiation. Despite the above mentioned resistance of
ErPC increases cytotoxicity of ionizing radiation in A172 cells Figure 4
ErPC increases cytotoxicity of ionizing radiation in A172 cells. A172 cells were irradiated with a single dose of 0, 2.5, 
5 or 10 Gy and subsequently treated with 0, 12.5, 25 or 50 µM ErPC as indicated. Induction of apoptosis and necrosis was 
quantified 24 h, 48 h and 72 h after treatment by fluorescence microscopy counting the cells with apoptotic and necrotic mor-
phology upon combined staining with Hoechst33342 and PI. The percentage of viable cells was calculated as indicated in Fig.1. 
Data show (A) one representative of three independent experiments (B, C, D) or means ± s.d. ; n = 3. (A) Morphologic 
appearance of A172 cells upon treatment with medium (control), 10 Gy, 50 µM ErPC or 10 Gy and 50 µM ErPC. (B) Increased 
efficacy of ErPC in combination with ionizing radiation depends on the radiation dose and the ErPC-concentration. (C and D) 
Increased efficacy of ErPC in combination with 10 or 5 Gy depends on the treatment time.
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T98G cells to radiation-induced apoptosis irradiation was
able to reduce clonogenic cell survival in a dose-depend-
ent manner (Fig. 11B+D). However, the combination
with ErPC or ErPC3 led to a further decrease in the sur-
vival of clonogenic T98G cells upon irradiaton (Fig.
11B+D). As visualized in Fig. 11B and 11D, combined
treatment of irradiated cells with increasing concentra-
tions of ErPC and ErPC3 led to a parallel shift of the
response curves at least at the low dose range indicative
for additive effects, while at higher doses additivity was
not reached. Interestingly, combined treatment with 16
µM ErPC3 and ionizing radiation was more efficient in
eradication of clonogenic tumor cells than the respective
combination with equimolar ErPC-concentrations.
Discussion
Based on the hypothesis that synthetic phospholipid
derivatives and ionizing radiation induce apoptosis via
distinct primary targets to trigger the intrinsic death path-
way, cytotoxic efficacy of combined treatment with both
therapies was evaluated in human malignant glioma cell
lines in vitro. In our investigation we demonstrate for the
first time that the prototypical intravenously applicable
APC-derivatives ErPC and ErPC3 increase the radiation
Increased cytotoxicity of ionizing radiation in combination with ErPC in U87MG cells Figure 5
Increased cytotoxicity of ionizing radiation in combination with ErPC in U87MG cells. U87MG cells were irradi-
ated with a single dose of 0, 2.5, 5 or 10 Gy and subsequently treated with 0, 50, 75 or 100 µM ErPC as indicated. Induction of 
cell death was quantified 24 h, 48 h and 72 h after treatment by fluorescence microscopy counting the cells with apoptotic and 
necrotic morphology upon combined staining with Hoechst 33342 and PI. The percentage of viable cells was calculated as indi-
cated in Fig.1. Data show (A) one representative of three independent experiments or (B, C, D) means ± s.d.; n = 3. (A) 
Morphologic appearance of U87MG cells upon treatment with medium (control), 10 Gy, 75 µM ErPC or 10 Gy and 75 µM 
ErPC. (B) Concentration- and dose-dependent increase in cytotoxic efficacy of the combination. (C and D) Time-dependent 
increase in cytotoxicity of ErPC in combination with 10 or 5 Gy.
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response of human malignant glioma cell lines. In short
term assays ErPC and ErPC3 enhanced sensitivity of these
highly resistant cells to radiation-induced cell death,
including apoptosis. Any combination of radiation with
ErPC was more effective than either treatment alone;
depending on the cell type, treatment time, dose level and
drug-concentration sub-additive, additive or synergistic
effects were observed. In long term colony formation
assays ErPC and ErPC3 were shown to efficiently kill clo-
nogenic tumor cells on their own and to increase radia-
tion-induced eradication of clonogenic tumor cells upon
combined treatment in an additive manner.
The observation of potent short term cytostatic and cyto-
toxic effects of ErPC and ErPC3 on human malignant gli-
oma cell lines in vitro is consistent with earlier
investigations in diverse human cancer cell lines including
malignant glioma ([24,29,30] and unpublished data). As
ErPC sensitizes human malignant glioma cell lines to radiation-induced cell death Figure 6
ErPC sensitizes human malignant glioma cell lines to radiation-induced cell death. Induction of apoptosis and clo-
nogenic cell survival was evaluated in U87MG, A172 and T98G cells upon irradiation (1–10 Gy) or treatment with ErPC (0–100 
µM). Cell death was quantified 24–72 h after treatment by fluorescence microscopy using combined staining with Hoechst 
33342 and propidium iodide. The biomathematical evaluation of putative additive or synergistic effects of the combination was 
performed by isobologram analysis [52]. Analysis of combined treatment efficacy was performed with 10 Gy and 25 µM ErPC 
(T98G, A172), or 10 Gy and 75 µM ErPC (U87MG) 48 h after treatment. Values located within the envelope of additivity (grey 
region) are indicative for additive effects, values located below the envelope of additivity are indicative for synergistic increase 
in cytotoxicity. Combined treatment with ErPC increases cytotoxic efficacy of ionizing radiation (10 Gy, 48 h) (A, B) in a syn-
ergistic (T98G, A172 cells) or (C) additive manner (U87MG cells).
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Results from isobologram analysis of combined treatment Figure 7
Results from isobologram analysis of combined treatment.
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a more clinically relevant end point we demonstrate that
these membrane targeted drugs reduce colony formation
in long term assays, indicative for eradication of clono-
genic tumor cells.
Up to now, only a few in vitro studies tested the efficacy of
synthetic phospholipid analogs in combination with ion-
izing radiation. In this regard, the APC-derivatives hexade-
cylphosphocholine (HePC) and Octadecyl-(N, N-
dimethyl-piperidinio-4-yl)-phosphate (D-21266; Perifo-
sine™) enhanced radiation-induced apoptosis of human
leukemic cell lines in an additive, the prototypical alkyl-
lysophospholipid Edelfosine (Et-18-OCH3; 1-O-Octade-
cyl-2-O-methyl-rac-glycero-3-phosphocholine) even in a
synergistic manner. Similar to ErPC and ErPC3, HePC was
able to overcome resistance of human tumor cells to radi-
ation-induced apoptosis. In line with our observations,
combined treatment of human epithelial tumor cell lines
with Et-18-OCH3 or HePC and ionizing radiation also
enhanced eradication of clonogenic tumor cells in colony
formation assays [22]. Thus, our data are consistent with
these reports on profitable in vitro effects of combined
treatment with synthetic phospholipid derivatives and
ionizing radiation regarding radiation-induced apoptosis
and clonogenic cell kill in human cancer cell lines.
ErPC3 exerts potent cytotoxic effects on T98G cells alone and in combination with ionizing radiation Figure 8
ErPC3 exerts potent cytotoxic effects on T98G cells alone and in combination with ionizing radiation. T98G 
were treated with 0–50 µM ErPC3 alone or in combination with 0, 2.5, 5 or 10 Gy for 48 h as indicated. Induction of apoptosis 
and necrosis was determined by fluorescence microscopy upon staining with Hoechst33342 and PI. The percentage of apop-
totic and necrotic cells was then quantified by counting of the cells with apoptotic and necrotic morphology, respectively. The 
percentage of viable cells was calculated as indicated in Fig.1. Data show (C) means ± s.d., n = 3 or (A, B, D) one representa-
tive of three independent experiments. (A) ErPC3 induces growth arrest and apoptosis in a dose-dependent manner in T98G 
cells as indicated by a decrease in cell density and increase in cells with apoptotic morphology. (B) Combined treatment with 
ErPC3 sensitizes T98G cells to radiation-induced growth arrest and apoptosis. (C) Increased efficacy of ErPC3 in combination 
with ionizing radiation depends on the radiation dose and drug concentration, respectively. (D) Isobolgram analysis of com-
bined treatment with 10 Gy and 25 µM ErPC3 after 48 h reveals synergistic effects.
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Interestingly, mechanistic investigations point to a critical
role of apoptosis induction for enhanced efficacy of the
combination. In this regard, notably for ErPC3 induction
of apoptosis was the major mode of cell death after short
time treatment. On molecular level, synergistic effects on
apoptosis induction upon combined treatment were
reflected by increased cleavage of the caspase-3 substrate
PARP. Moreover, synergistic effects on apoptosis induc-
tion involved enhanced mitochondrial damage. Thus,
beneficial effects of these novel drugs on efficacy of ioniz-
ing radiation may at least partially be due to increased
apoptosis induction at the level of the mitochondria.
However, the significance of apoptosis for long term radi-
ation responses of tumor cells and normal tissues is still
controversial and was suggested to depend on the cellular
system [34,35]. In our hands quantification of apoptosis
induction in short term assays was not predictive for the
radiation response in colony formation assays with
respect to ionizing radiation alone. However, efficient
induction of apoptosis upon treatment with ErPC alone
or in combination with ionizing radiation was associated
with increased eradication of clonogenic tumor cells in
colony formation assays. Thus, the combination of ioniz-
ing radiation and the apoptosis modulators ErPC and
ErPC3 can clearly increase efficacy of radiation treatment.
Similar results were recently obtained using ionizing radi-
ation in combination with the proapoptotic tumor necro-
sis factor alpha related apoptosis inducing ligand TRAIL
[36,37] and the protein kinase inhibitor PKC412, respec-
tively [38]. However, it has to be considered, that cell cycle
Increased induction of apoptosis contributes to increased efficacy of the combination Figure 9
Increased induction of apoptosis contributes to increased efficacy of the combination. (A, B) T98G cells were 
treated with a single dose of 10 Gy and subsequently treated with 0, 12.5, 25 or 50 µM ErPC or ErPC3 as indicated. The 
amount of apoptotic and necrotic cells was determined 48 h after treatment by fluorescence microscopy upon staining with 
Hoechst33342 and PI and counting of the cells with apoptotic morphology and necrotic morphology, respectively. (C) T98G 
cells were treated with a single dose of 5 Gy and subsequently treated with 0 or 25 µM ErPC. Cleavage of the caspase-3 sub-
strate PARP was determined by Western blotting of cytosolic extracts obtained 24 h after treatment. (A) Dose dependent 
increase in the percentage of apoptotic and necrotic T98G cells upon combined treatment with increasing concentrations of 
ErPC and 10 Gy. (B) Efficient Increase in the percentage of apoptotic T98G cells upon combined treatment with ErPC3 and 10 
Gy. (C) Improved cleavage of PARP upon combined treatment with 25 µM ErPC and 5 Gy. Data show (A, B) means ± s.d., n 
= 3 or (C) one representative of three independent experiments.
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arrest in G2 also contributes to the toxicity of ErPC/ErPC3
in human glioblastoma cells (data not shown).
Although several synthetic phospholipid derivatives dis-
played promising antineoplastic activity in preclinical
investigations, it has to be taken into account that only
few drugs may be suited for future clinical drug develop-
ment. Despite its potent antineoplastic action in vitro the
in vivo activity of the prototypical alkyllysophospholipid
derivative Et-18-OCH3 is only moderate. This was attrib-
uted to the high level of biotransformation after systemic
application that results in a lack of tissue accumulation
[39]. Hemolytic side effects of HePC, the first APC-deriva-
tive successfully introduced into the clinic, preclude its
intravenous application. Consequently, clinical use of
HePC is either limited to topical application as an effec-
tive palliative treatment option for skin metastases of
breast cancer patients as well as for cutaneous malignant
lymphoma (Miltex™) [40-44] or to oral application
(Impavido™). Daily doses of 100 mg HePC which have
been shown to be insufficient for cancer treatment have
been proven to cure visceral leishmaniasis [45]. Dose
escalation of orally given HePC is prevented by gastroin-
testinal toxicity.
Perifosine, a heterocyclic APC, showed promising antine-
oplastic activity in preclinical investigations [46] and
already entered clinical Phase I and Phase II trials to test
feasibility and tolerability of oral administration of the
drug alone and in combination with radiotherapy in
patients with advanced solid tumors. Oral administration
of Perifosine is safe and mainly results in fatigue and gas-
trointestinal side-effects while no hematological toxicity
could be observed [19,47-50]. Unfortunately, no signifi-
Increased pro-apoptotic efficacy of the combination involves enhanced damage of the mitochondria Figure 10
Increased pro-apoptotic efficacy of the combination involves enhanced damage of the mitochondria. T98G were 
irradiated with a single dose of 0, 2.5, 5 or 10 Gy and subsequently treated with 0, 12.5, 25 or 50 µM ErPC as indicated. Induc-
tion of apoptosis was quantified 48 h after treatment by FACS upon staining with TMRE. Data show (A) means ± s.d., n = 3 or 
(B) original histograms of one representative experiment.
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cant clinical activity was found after single drug adminis-
tration in patients with metastatic melanoma and
androgen independent prostate cancer [49,50].
In contrast to the above mentioned drugs, ErPC and its
derivative ErPC3 lack hemolytic side effects and thus con-
stitute the first synthetic phospholipid analogs that are
suited for intravenous administration. After repeated i.v.
applications of nontoxic drug doses ErPC accumulates in
diverse tissues of healthy rats including the brain tissue
[31]. Fortunately, ErPC and ErPC3 are even more potent
than HePC in preclinical investigations [29,51].
Intriguingly, in our in vitro study ErPC3 was a more effec-
tive inducer of apoptosis in T98G cells than ErPC when
given alone and in combination with ionizing radiation.
Moreover, in colony formation assays ErPC3 also proved
to be the more active when used as single drug or in com-
bination with ionizing radiation. In this regard, similar
eradication of clonogenic tumor cells required 16 µM
ErPC3 or 20 µM ErPC, respectively. The same holds true
for combined treatment with 10 Gy and 16 µM ErPC3
compared to 10 Gy and 25 µM ErPC.
The above mentioned findings on improved antineoplas-
tic activity compared to ErPC together with its higher sol-
ErPC and ErPC3 decrease the number of clonogenic T98G cells and increase radiation-induced eradication of clonogenic T98G  cells Figure 11
ErPC and ErPC3 decrease the number of clonogenic T98G cells and increase radiation-induced eradication of 
clonogenic T98G cells. Effects of ErPC and ErPC3 alone or in combination with ionizing radiation on clonogenic cell survival 
was determined by standard colony formation assays. 24 h after plating T98G cells were treated with increasing concentrations 
of (A) ErPC or (C) ErPC3 alone or (B, D) in combination with ionizing radiation with 0, 2.5, 5 and 10 Gy. In the latter case, 
ErPC or ErPC3 were added 10 min after irradiation. Subsequently, cells were incubated under standard culturing conditions up 
to 4 weeks. For determination of colony formation cells were fixed in 3.7% paraformaldehyde and 70% ethanol and stained 
with 0.05% Coomassie blue. Colonies composed of at least 50 cells were counted. Data represent means ± s.d., n = 3
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ubility in aqueous solutions that allows simplified
intravenous administration in vivo, favor ErPC3 for further
clinical development. Consequently, a clinical Phase I
trial was initiated at the Department of Internal Medicine
III, University Hospital Grosshadern, Munich, Germany,
to test feasibility and tolerability of intravenous adminis-
tration of ErPC3 to patients with advanced malignancies.
As the maximum tolerated dose (MTD) of ErPC3 has not
yet been reached, patient recruitment goes on (Dr. L. H.
Lindner, Dept. of Internal Medicine III, University Hospi-
tal Grosshadern, Munich, Germany, personal communi-
cation).
In summary our study demonstrates increased efficacy of
ionizing radiation in combination with the proapoptotic
membrane targeted apoptosis modulators ErPC and
ErPC3 in human malignant glioma cell lines in vitro. Both
drugs sensitized human malignant glioma cell lines to
radiation-induced cell death including apoptosis and
enhanced radiation-induced eradication of clonogenic
tumor cells. The improved efficacy of ErPC3 compared to
ErPC make this APC derivative a promising tool for inno-
vative combined treatment approaches in the therapy of
patients suffering from malignant glioma. The molecular
requirements for the increased efficacy of radiation ther-
apy in combination with ErPC and ErPC3 require further
definition.
Methods
Chemicals and drugs
ErPC and ErPC3 were synthesized by H. Eibl, Max Planck
Institute of Biophysical Chemistry, Goettingen, Germany.
For in vitro experiments, ErPC was dissolved in 200 µl eth-
anol, and diluted with RPMI1640 medium supplemented
with 10% (v/v) fetal calf serum to a concentration of 10
mM (stock solution). The final ethanol concentrations in
the tissue culture experiments were below 0.05% (v/v).
ErPC3 was dissolved in RPMI1640 medium supple-
mented with 10% (v/v) fetal calf serum to a concentration
of 10 mM (stock solution) without prior dissolution in
ethanol. Hoechst33342 (Calbiochem, Bad Soden, Ger-
many) was dissolved in distilled water as a 1.5 mM stock
solution. Propidium Iodide (Sigma) was dissolved in dis-
tilled water as a 5 mg/ml stock solution.
Rabbit anti-full length anti-PARP and rabbit anti-cleaved
PARP were from Cell Signaling (New England Biolabs,
Schwalbach/Taunus, Germany). Mouse β-actin was from
Sigma. HRP-conjugated anti-rabbit secondary antibodies
were obtained from Amersham-Biosciences, Freiburg,
Germany.
All other chemicals were purchased from Sigma-Aldrich
(Deisenhofen, Germany) if not otherwise specified.
Cell lines, cell culture and cellular treatment
T98G, U87MG and A172 astrocytoma/glioblastoma cell
lines were from ATCC (Bethesda, Maryland, USA). For all
experiments cells were grown in RPMI 1640 medium sup-
plemented with 10% (v/v) fetal calf serum (Gibco Life
Technologies, Eggenstein, Germany) and maintained in a
humidified incubator at 37°C and 5% CO2.
Irradiation was performed at room temperature with 6
MV photons from Siemens or Elekta linear accelerators
with a dose rate of 2 or 4 Gy per min, respectively.
Determination of apoptosis
Cell death was analyzed by fluorescence microscopy upon
combined staining of the cells with Hoechst33342 and
propidium iodide (PI) to discriminate between apoptotic
and necrotic cells. In brief, cells were incubated with
Hoechst33342 at a final concentration of 1.5 µM and PI at
a final concentration of 2.5 µg/ml for 10 min. Cell mor-
phology was determined by fluorescence microscopy
(Zeiss Axiovert 200, Carl Zeiss, Jena, Germany) using a
G365/FT395/LP420 filterset. Cells were analyzed at x40
magnification and documented using a CCD camera
device (Zeiss Axiocam MR). Apoptotic cells (blue or rose
stained nuclei with apoptotic nuclear morphology) and
necrotic cells (rose stained nuclei without fragmentation)
were quantified by cell counting.
Determination of PARP-cleavage
PARP cleavage was determined by Western blot analysis of
cytosolic extracts. To this end, cells (1 × 107/ml) were
lyzed for 10 min at 99°C in CST lysis buffer (62.5 mM
Tris-HCl (pH 6,8), 2% (w/v) SDS, 10% (v/v) glycerol, 50
mM DTT, 0.01% (w/v) bromphenolblue). 20 µg lysate
were separated by SDS-PAGE and blotted onto PVDF-
membranes (Roth, Karlsruhe, Germany). Blots were
blocked for 1 h in PBS buffer containing 0.05% (v/v)
Tween 20 and 5% (w/v) non fat dried milk. The mem-
brane was incubated over night at 4°C with the respective
primary antibody (anti-PARP; anti-cleaved PARP;
1:1000). After repeated washings with TBS/Tween-20
(0.05%, v/v) the membrane was incubated for 1 h at room
temperature with the secondary antibody (anti-IgG-AP
1:2000, Santa-Cruz-Biotech, Heidelberg, Germany) and
again washed several times with TBS/Tween. The detec-
tion of antibody binding was performed by enhanced
chemoluminescence staining (ECL Western blotting anal-
ysis system, Amersham-Biosciences, Freiburg, Germany).
Equal protein loading was confirmed by Coomassie stain
and β-actin detection.
Determination of mitochondrial membrane potential
The mitochondrial transmembrane potential (∆Ψm) was
analyzed by flow cytometry using the ∆Ψm-specific stain
TMRE (tetramethylrhodamine-ethylester-perchlorate)Radiation Oncology 2006, 1:6 http://www.ro-journal.com/content/1/1/6
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(Molecular Probes, Mobitech, Goettingen Germany). To
this end, cells were loaded for 30 min at 37°C with 25 nM
TMRE and subsequently analyzed by flow cytometry. Pre-
incubation with 1 µM of the proton ionophore CCCP
(carbonylcyanide-m-chlorophenylhydrazone) was used
as a positive control for complete depolarization.
Colony formation assays
Exponentially grown cells were harvested and seeded in 6
well tissue culture plates or flasks at a density of 50 to 128
000 cells depending on irradiation and ErPC doses. After
24 h cells were irradiated (2.5, 5 or 10 Gy), treated with
ErPC (12.5–100 µM) or submitted to combined treat-
ment. Subsequently, cells were incubated under standard
culturing conditions (37°C/5% CO2) up to 4 weeks
depending on treatment. For determination of colony for-
mation cells were fixed in 3.7% formaldehyde and 70%
ethanol. Fixed cells were stained with 0.05% Coomassie
blue.
Colonies of at least 50 cells were counted. The surviving
fraction of treated cultures was calculated by dividing the
number of colonies by the plating efficiency of untreated
cells. The survival curve was established by plotting the
log of the surviving fraction versus the irradiation dose.
Statistical analysis
Efficacy of the combined treatment modalities was evalu-
ated by isobologram analysis [52]. Based on the measured
values for single treatment regimens, data for combined
treatment were extrapolated defining a calculated area of
additive treatment response (envelope of additivity) [52].
The given results of the experiments were then compared
to the calculated data: values within the envelope of addi-
tivity are representative for an additive effect, while values
below this envelope indicate a synergism between both
treatment modalities. In contrast, values above the enve-
lope of additivity are indicative for sub-additive effects.
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